Investor Presentaiton

26 Investor presentation Full year 2022 The acquisition of Dicerna Pharmaceuticals and their RNAi technology in 2021 provided access to intracellular targets Disease targets (expressed genes) • Opportunity to silence genes Cell ~5,000 extracellular targets ~21,000 intracellular targets • Drugability of intracellular targets • RNA: Ribonucleic acid; mRNA: messenger RNA • Genes (DNA) on chromosomes Peptides and proteins m RNAi mRNA Highly specific for targeted gene Reversible yet long-acting therapies Engage on the temporary genetic level with RNA therapeutics Novo NordiskⓇ

View entire presentation